{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:20:36Z","timestamp":1783570836275,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University \u201cG. d\u2019Annunzio\u201d, Italy","award":["RESEARCH GRANT EX-60%"],"award-info":[{"award-number":["RESEARCH GRANT EX-60%"]}]},{"name":"University \u201cG. d\u2019Annunzio\u201d, Italy","award":["RESEARCH GRANT EX-60%"],"award-info":[{"award-number":["RESEARCH GRANT EX-60%"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immun Ageing"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Natural antibodies (nAbs) against aggregation-prone proteins have been found in healthy normal subjects. These proteins likely have a pathogenetic role in neurodegenerative diseases of ageing. They include the amyloid \u03b2 (A\u03b2) protein which may play an important role in Alzheimer\u2019s dementia (AD), and \u03b1-synuclein, a major determinant of Parkinson\u2019s disease (PD). We measured nAbs to A\u03b2 in a group of Italian patients with AD, vascular dementia, non-demented PD patients and healthy elderly controls. We found that A\u03b2 antibody levels in AD were similar to age- and sex-matched controls, but contrary to our expectations, they were significantly reduced in PD. This may identify patients that could be more prone to amyloid aggregation.<\/jats:p>","DOI":"10.1186\/s12979-023-00336-w","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:23:13Z","timestamp":1679862193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Natural IgG antibodies to \u03b2 amyloid are decreased in patients with Parkinson\u2019s disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Roberto","family":"Paganelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Pawelec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"336_CR1","doi-asserted-by":"crossref","unstructured":"Spillantini MG. Parkinson\u2019s disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord. 1999;5(4):157\u201362.","DOI":"10.1016\/S1353-8020(99)00031-0"},{"key":"336_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fnins.2017.00064","volume":"11","author":"E Stroo","year":"2017","unstructured":"Stroo E, Koopman M, Nollen EA, Mata-Cabana A. Cellular regulation of amyloid formation in aging and disease. Front Neurosci. 2017;11:64.","journal-title":"Front Neurosci"},{"key":"336_CR3","doi-asserted-by":"crossref","unstructured":"Weksler ME, Gouras G, Relkin NR, Szabo P. The immune system, amyloid-beta peptide, and Alzheimer\u2019s disease. Immunol Rev. 2005;205:244\u201356.","DOI":"10.1111\/j.0105-2896.2005.00264.x"},{"key":"336_CR4","doi-asserted-by":"crossref","unstructured":"Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. Safety and tolerability of BAN2401\u2013a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8(1):14.","DOI":"10.1186\/s13195-016-0181-2"},{"key":"336_CR5","doi-asserted-by":"crossref","unstructured":"Li XW, Li XX, Liu QS, Cheng Y. Blood and Cerebrospinal Fluid Autoantibody to Abeta Levels in Patients with Alzheimer\u2019s Disease: a Meta-Analysis Study. J Mol Neurosci. 2020;70(8):1208\u201315.","DOI":"10.1007\/s12031-020-01528-5"},{"issue":"1","key":"336_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14(1):38\u201348.","journal-title":"Nat Rev Neurosci"},{"key":"336_CR7","doi-asserted-by":"crossref","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"336_CR8","doi-asserted-by":"crossref","unstructured":"Volloch V, Olsen B, Rits S. Alzheimer\u2019s Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, betaAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow. Ann Integr Mol Med. 2020;2(1):90\u2013114.","DOI":"10.33597\/aimm.02-1007"},{"issue":"6","key":"336_CR9","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/molecules27061776","volume":"27","author":"S Subedi","year":"2022","unstructured":"Subedi S, Sasidharan S, Nag N, Saudagar P, Tripathi T. Amyloid Cross-Seeding: Mechanism, Implication, and Inhibition. Molecules. 2022;27(6):1776.","journal-title":"Molecules"},{"key":"336_CR10","doi-asserted-by":"crossref","unstructured":"Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer\u2019s and Parkinson\u2019s in dementia with Lewy body disease. Neurochem Res. 2006;31(9):1153\u201362.","DOI":"10.1007\/s11064-006-9140-9"},{"issue":"21","key":"336_CR11","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281\u20139.","journal-title":"J Neurosci"},{"issue":"6","key":"336_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.autrev.2008.04.010","volume":"7","author":"F Neff","year":"2008","unstructured":"Neff F, Wei X, Nolker C, Bacher M, Du Y, Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev. 2008;7(6):501\u20137.","journal-title":"Autoimmun Rev"},{"key":"336_CR13","doi-asserted-by":"crossref","unstructured":"Maetzler W, Apel A, Langkamp M, Deuschle C, Dilger SS, Stirnkorb JG, et al. Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson\u2019s disease patients and controls. PLoS One. 2014;9(2):e88604.","DOI":"10.1371\/journal.pone.0088604"},{"key":"336_CR14","doi-asserted-by":"crossref","unstructured":"Liu YH, Wang J, Li QX, Fowler CJ, Zeng F, Deng J, et al. Association of naturally occurring antibodies to beta-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer\u2019s disease. Sci Adv. 2021;7(1):eabb0457.","DOI":"10.1126\/sciadv.abb0457"},{"issue":"7","key":"336_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","volume":"37","author":"ME Weksler","year":"2002","unstructured":"Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37(7):943\u20138.","journal-title":"Exp Gerontol"},{"issue":"5","key":"336_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/WNL.57.5.801","volume":"57","author":"Y Du","year":"2001","unstructured":"Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57(5):801\u20135.","journal-title":"Neurology"},{"key":"336_CR17","doi-asserted-by":"crossref","unstructured":"Qu BX, Gong Y, Moore C, Fu M, German DC, Chang LY, et al. Beta-amyloid auto-antibodies are reduced in Alzheimer\u2019s disease. J Neuroimmunol. 2014;274(1\u20132):168\u201373.","DOI":"10.1016\/j.jneuroim.2014.06.017"},{"issue":"3","key":"336_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00002093-200607000-00001","volume":"20","author":"L Jianping","year":"2006","unstructured":"Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3):127\u201332.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"336_CR19","doi-asserted-by":"crossref","unstructured":"Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Burger K, Dodel R, et al. Decreased serum amyloid beta(1\u201342) autoantibody levels in Alzheimer\u2019s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1\u201342) peptide. Biol Psychiatry. 2005;57(7):813\u20136.","DOI":"10.1016\/j.biopsych.2004.12.008"},{"key":"336_CR20","doi-asserted-by":"crossref","unstructured":"Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, et al. Autoimmunity in Alzheimer\u2019s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging. 2004;25(8):1023\u201332.","DOI":"10.1016\/j.neurobiolaging.2003.11.001"},{"key":"336_CR21","doi-asserted-by":"crossref","unstructured":"Klaver AC, Coffey MP, Smith LM, Bennett DA, Finke JM, Dang L, et al. ELISA measurement of specific non-antigen-bound antibodies to Abeta1-42 monomer and soluble oligomers in sera from Alzheimer\u2019s disease, mild cognitively impaired, and noncognitively impaired subjects. J Neuroinflammation. 2011;8:93.","DOI":"10.1186\/1742-2094-8-93"},{"key":"336_CR22","doi-asserted-by":"crossref","unstructured":"Wang A, Das P, Switzer RC 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer\u2019s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci. 2011;31(11):4124\u201336.","DOI":"10.1523\/JNEUROSCI.5077-10.2011"},{"issue":"11","key":"336_CR23","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1089\/hum.2009.219","volume":"21","author":"N Movsesyan","year":"2010","unstructured":"Movsesyan N, Davtyan H, Mkrtichyan M, Petrushina I, Tiraturyan T, Ross T, et al. Low concentrations of anti-Abeta antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. Hum Gene Ther. 2010;21(11):1569\u201376.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"336_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000090366","volume":"2","author":"D Morgan","year":"2005","unstructured":"Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis. 2005;2(5):261\u20136.","journal-title":"Neurodegener Dis"},{"key":"336_CR25","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3389\/fimmu.2019.01534","volume":"10","author":"Y Chantran","year":"2019","unstructured":"Chantran Y, Capron J, Alamowitch S, Aucouturier P. Anti-Abeta Antibodies and Cerebral Amyloid Angiopathy Complications. Front Immunol. 2019;10:1534.","journal-title":"Front Immunol"},{"key":"336_CR26","doi-asserted-by":"crossref","unstructured":"Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2004;75(10):1472\u20134.","DOI":"10.1136\/jnnp.2003.033399"},{"key":"336_CR27","doi-asserted-by":"crossref","unstructured":"Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013;12(3):233\u201343.","DOI":"10.1016\/S1474-4422(13)70014-0"},{"key":"336_CR28","doi-asserted-by":"crossref","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","DOI":"10.1038\/nature19323"},{"issue":"6","key":"336_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000478741","volume":"17","author":"Y Wang","year":"2017","unstructured":"Wang Y, Yan T, Lu H, Yin W, Lin B, Fan W, et al. Lessons from Anti-Amyloid-beta Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. Neurodegener Dis. 2017;17(6):242\u201350.","journal-title":"Neurodegener Dis"},{"issue":"4","key":"336_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000511506","volume":"49","author":"A Tian Hui Kwan","year":"2020","unstructured":"Tian Hui Kwan A, Arfaie S, Therriault J, Rosa-Neto P, Gauthier S. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. Dement Geriatr Cogn Disord. 2020;49(4):334\u201348.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6604","key":"336_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.add9993","volume":"377","author":"C Piller","year":"2022","unstructured":"Piller C. Blots on a field? Science. 2022;377(6604):358\u201363.","journal-title":"Science"},{"key":"336_CR32","doi-asserted-by":"publisher","first-page":"113168","DOI":"10.1016\/j.biopha.2022.113168","volume":"152","author":"R Malik","year":"2022","unstructured":"Malik R, Kalra S, Bhatia S, Harrasi AA, Singh G, Mohan S, et al. Overview of therapeutic targets in management of dementia. Biomed Pharmacother. 2022;152:113168.","journal-title":"Biomed Pharmacother"},{"key":"336_CR33","doi-asserted-by":"crossref","unstructured":"Luo JJ, Wallace W, Kusiak JW. A tough trek in the development of an anti-amyloid therapy for Alzheimer\u2019s disease: do we see hope in the distance? J Neurol Sci. 2022;438:120294.","DOI":"10.1016\/j.jns.2022.120294"},{"key":"336_CR34","doi-asserted-by":"crossref","unstructured":"Akhtar RS, Licata JP, Luk KC, Shaw LM, Trojanowski JQ, Lee VM. Measurements of auto-antibodies to alpha-synuclein in the serum and cerebral spinal fluids of patients with Parkinson\u2019s disease. J Neurochem. 2018;145(6):489\u2013503.","DOI":"10.1111\/jnc.14330"},{"key":"336_CR35","doi-asserted-by":"crossref","unstructured":"Bach JP, Falkenburger BH. What autoantibodies tell us about the pathogenesis of Parkinson\u2019s disease: an Editorial for \u201cMeasurements of auto-antibodies to alpha-synuclein in the serum and cerebral spinal fluids of patients with Parkinson\u2019s disease\u201d on page 489. J Neurochem. 2018;145(6):433\u20135.","DOI":"10.1111\/jnc.14340"},{"key":"336_CR36","doi-asserted-by":"crossref","unstructured":"Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson\u2019s disease patients. PLoS One. 2011;6(4):e18513.","DOI":"10.1371\/journal.pone.0018513"},{"key":"336_CR37","doi-asserted-by":"crossref","unstructured":"Shalash A, Salama M, Makar M, Roushdy T, Elrassas HH, Mohamed W, et al. Elevated Serum alpha-Synuclein Autoantibodies in Patients with Parkinson\u2019s Disease Relative to Alzheimer\u2019s Disease and Controls. Front Neurol. 2017;8:720.","DOI":"10.3389\/fneur.2017.00720"},{"key":"336_CR38","doi-asserted-by":"crossref","unstructured":"Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson\u2019s disease. J Neurochem. 2007;101(3):749\u201356.","DOI":"10.1111\/j.1471-4159.2006.04365.x"},{"issue":"2","key":"336_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.0b013e31827b90d1","volume":"80","author":"D Besong-Agbo","year":"2013","unstructured":"Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, Poewe W, et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology. 2013;80(2):169\u201375.","journal-title":"Neurology"},{"key":"336_CR40","doi-asserted-by":"crossref","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344.","DOI":"10.1212\/WNL.34.7.939"},{"key":"336_CR41","doi-asserted-by":"crossref","unstructured":"Vasconcellos LF, Pereira JS. Parkinson\u2019s disease dementia: Diagnostic criteria and risk factor review. J Clin Exp Neuropsychol. 2015;37(9):988\u201393.","DOI":"10.1080\/13803395.2015.1073227"},{"key":"336_CR42","doi-asserted-by":"crossref","unstructured":"Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l\u2019Enseignement en Neurosciences. Stroke. 2000;31(12):2952\u20137.","DOI":"10.1161\/01.STR.31.12.2952"},{"issue":"6","key":"336_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.autrev.2008.03.007","volume":"7","author":"P Szabo","year":"2008","unstructured":"Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev. 2008;7(6):415\u201320.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"336_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jneumeth.2010.01.018","volume":"187","author":"AC Klaver","year":"2010","unstructured":"Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA. Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods. 2010;187(2):263\u20139.","journal-title":"J Neurosci Methods"},{"issue":"1\u20132","key":"336_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jneuroim.2010.06.010","volume":"227","author":"P Szabo","year":"2010","unstructured":"Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol. 2010;227(1\u20132):167\u201374.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"336_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JAD-2010-1353","volume":"20","author":"K Balakrishnan","year":"2010","unstructured":"Balakrishnan K, Andrei-Selmer LC, Selmer T, Bacher M, Dodel R. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J Alzheimers Dis. 2010;20(1):135\u201343.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"336_CR47","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jneumeth.2010.12.001","volume":"195","author":"AC Klaver","year":"2011","unstructured":"Klaver AC, Patrias LM, Finke JM, Loeffler DA. Specificity and sensitivity of the Abeta oligomer ELISA. J Neurosci Methods. 2011;195(2):249\u201354.","journal-title":"J Neurosci Methods"},{"issue":"3","key":"336_CR48","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1212\/NXI.0000000000000237","volume":"3","author":"EM Knight","year":"2016","unstructured":"Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, et al. Effective anti-Alzheimer Abeta therapy involves depletion of specific Abeta oligomer subtypes. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e237.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"38","key":"336_CR49","doi-asserted-by":"publisher","first-page":"11220","DOI":"10.1021\/jp506258g","volume":"118","author":"TD Do","year":"2014","unstructured":"Do TD, Economou NJ, Chamas A, Buratto SK, Shea JE, Bowers MT. Interactions between amyloid-beta and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. J Phys Chem B. 2014;118(38):11220\u201330.","journal-title":"J Phys Chem B"},{"key":"336_CR50","doi-asserted-by":"publisher","first-page":"109120","DOI":"10.1016\/j.abb.2022.109120","volume":"717","author":"E Chau","year":"2022","unstructured":"Chau E, Kim JR. alpha-synuclein-assisted oligomerization of beta-amyloid (1\u201342). Arch Biochem Biophys. 2022;717:109120.","journal-title":"Arch Biochem Biophys"},{"issue":"15","key":"336_CR51","doi-asserted-by":"publisher","first-page":"e2025847118","DOI":"10.1073\/pnas.2025847118","volume":"118","author":"D Trudler","year":"2021","unstructured":"Trudler D, Nazor KL, Eisele YS, Grabauskas T, Dolatabadi N, Parker J, et al. Soluble alpha-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proc Natl Acad Sci U S A. 2021;118(15):e2025847118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"336_CR52","doi-asserted-by":"crossref","unstructured":"Diaz-Ortiz ME, Seo Y, Posavi M, Carceles Cordon M, Clark E, Jain N, et al. GPNMB confers risk for Parkinson\u2019s disease through interaction with alpha-synuclein. Science. 2022;377(6608):eabk0637.","DOI":"10.1126\/science.abk0637"},{"issue":"1","key":"336_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.intimp.2009.10.005","volume":"10","author":"AC Klaver","year":"2010","unstructured":"Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol. 2010;10(1):115\u20139.","journal-title":"Int Immunopharmacol"},{"key":"336_CR54","doi-asserted-by":"crossref","unstructured":"Viola KL, Bicca MA, Bebenek AM, Kranz DL, Nandwana V, Waters EA, et al. The Therapeutic and Diagnostic Potential of Amyloid beta Oligomers Selective Antibodies to Treat Alzheimer\u2019s Disease. Front Neurosci. 2021;15:768646.","DOI":"10.3389\/fnins.2021.768646"},{"issue":"15","key":"336_CR55","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.3390\/ijms21155295","volume":"21","author":"KY Sim","year":"2020","unstructured":"Sim KY, Im KC, Park SG. The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease. Int J Mol Sci. 2020;21(15):5295.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"336_CR56","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/ced.14269","volume":"45","author":"A Paganelli","year":"2020","unstructured":"Paganelli A, Tarentini E, Benassi L, Kaleci S, Magnoni C. Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clin Exp Dermatol. 2020;45(7):824\u201330.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"336_CR57","doi-asserted-by":"publisher","first-page":"e13247","DOI":"10.1111\/dth.13247","volume":"33","author":"A Paganelli","year":"2020","unstructured":"Paganelli A, Kaleci S, Benassi L, Pellacani G, Magnoni C. Mesenchymal stem cells and psoriasis: state of the art and future perspectives. Dermatol Ther. 2020;33(2):e13247.","journal-title":"Dermatol Ther"},{"issue":"7858","key":"336_CR58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41586-021-03489-0","volume":"593","author":"S Da Mesquita","year":"2021","unstructured":"Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, et al. Meningeal lymphatics affect microglia responses and anti-Abeta immunotherapy. Nature. 2021;593(7858):255\u201360.","journal-title":"Nature"},{"key":"336_CR59","doi-asserted-by":"crossref","unstructured":"DiFrancesco JC, Longoni M, Piazza F. Anti-Abeta Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy. Front Neurol. 2015;6:207.","DOI":"10.3389\/fneur.2015.00207"},{"issue":"3","key":"336_CR60","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-Related Imaging Abnormalities and beta-Amyloid-Targeting Antibodies: A Systematic Review. JAMA Neurol. 2022;79(3):291\u2013304.","journal-title":"JAMA Neurol"},{"key":"336_CR61","doi-asserted-by":"crossref","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, MarsicaGrassi C, et al. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer\u2019s Disease Treated with Anti-Amyloid Beta Therapy. J Prev Alzheimers Dis. 2022;9(2):211\u201320.","DOI":"10.14283\/jpad.2022.21"},{"issue":"1","key":"336_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey ED, Bussiere T, Rajagovindan R, Sebalusky J, Hamann S, von Hehn C, et al. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol. 2022;144(1):143\u201353.","journal-title":"Acta Neuropathol"},{"key":"336_CR63","doi-asserted-by":"crossref","unstructured":"Emrani S, Lamar M, Price CC, Wasserman V, Matusz E, Au R, et al. Alzheimer\u2019s\/Vascular Spectrum Dementia: Classification in Addition to Diagnosis. J Alzheimers Dis. 2020;73(1):63\u201371.","DOI":"10.3233\/JAD-190654"},{"issue":"2","key":"336_CR64","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jalz.2017.07.755","volume":"14","author":"MR Azarpazhooh","year":"2018","unstructured":"Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement. 2018;14(2):148\u201356.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"336_CR65","doi-asserted-by":"publisher","first-page":"e0177924","DOI":"10.1371\/journal.pone.0177924","volume":"12","author":"RS Akhtar","year":"2017","unstructured":"Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, et al. Regional brain amyloid-beta accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE. 2017;12(5):e0177924.","journal-title":"PLoS ONE"},{"key":"336_CR66","doi-asserted-by":"crossref","unstructured":"George S, Brundin P. Immunotherapy in Parkinson\u2019s Disease: Micromanaging Alpha-Synuclein Aggregation. J Parkinsons Dis. 2015;5(3):413\u201324.","DOI":"10.3233\/JPD-150630"},{"key":"336_CR67","doi-asserted-by":"crossref","unstructured":"Kronimus Y, Albus A, Balzer-Geldsetzer M, Straub S, Semler E, Otto M, et al. Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson\u2019s Disease Dementia. PLoS One. 2016;11(11):e0164953.","DOI":"10.1371\/journal.pone.0164953"},{"key":"336_CR68","doi-asserted-by":"crossref","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc Natl Acad Sci U S A. 2001;98(21):12245\u201350.","DOI":"10.1073\/pnas.211412398"},{"key":"336_CR69","doi-asserted-by":"crossref","unstructured":"Davtyan H, Zagorski K, Rajapaksha H, Hovakimyan A, Davtyan A, Petrushina I, et al. Alzheimer\u2019s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Abeta pathological molecules. Sci Rep. 2016;6:28912.","DOI":"10.1038\/srep28912"},{"issue":"Suppl 1","key":"336_CR70","first-page":"S67","volume":"33","author":"R Kayed","year":"2013","unstructured":"Kayed R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis. 2013;33(Suppl 1):S67-78.","journal-title":"J Alzheimers Dis"},{"issue":"Pt 5","key":"336_CR71","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/brain\/awq056","volume":"133","author":"A Serrano-Pozo","year":"2010","unstructured":"Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain. 2010;133(Pt 5):1312\u201327.","journal-title":"Brain"},{"issue":"3","key":"336_CR72","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","volume":"138","author":"E Valera","year":"2013","unstructured":"Valera E, Masliah E. Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies. Pharmacol Ther. 2013;138(3):311\u201322.","journal-title":"Pharmacol Ther"},{"key":"336_CR73","doi-asserted-by":"crossref","unstructured":"Vaz M, Silva V, Monteiro C, Silvestre S. Role of Aducanumab in the Treatment of Alzheimer\u2019s Disease: Challenges and Opportunities. Clin Interv Aging. 2022;17:797\u2013810.","DOI":"10.2147\/CIA.S325026"},{"issue":"4","key":"336_CR74","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21(4):306\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"336_CR75","doi-asserted-by":"crossref","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321.","DOI":"10.1056\/NEJMoa2212948"},{"key":"336_CR76","doi-asserted-by":"crossref","unstructured":"Gandy S, Ehrlich ME. Moving the Needle on Alzheimer\u2019s Disease with an Anti-Oligomer Antibody. N Engl J Med. 2023;388(1):80\u20131.","DOI":"10.1056\/NEJMe2214981"},{"key":"336_CR77","doi-asserted-by":"crossref","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N Engl J Med. 2022;387(5):421\u201332.","DOI":"10.1056\/NEJMoa2202867"},{"key":"336_CR78","doi-asserted-by":"crossref","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. Trial of Cinpanemab in Early Parkinson\u2019s Disease. N Engl J Med. 2022;387(5):408\u201320.","DOI":"10.1056\/NEJMoa2203395"},{"key":"336_CR79","doi-asserted-by":"crossref","unstructured":"Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S, et al. Aging and Parkinson\u2019s Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radic Biol Med. 2018;115:80\u201391.","DOI":"10.1016\/j.freeradbiomed.2017.10.379"},{"key":"336_CR80","doi-asserted-by":"crossref","unstructured":"Whone A. Monoclonal Antibody Therapy in Parkinson\u2019s Disease - The End? N Engl J Med. 2022;387(5):466\u20137.","DOI":"10.1056\/NEJMe2207681"}],"container-title":["Immunity &amp; Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-023-00336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12979-023-00336-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-023-00336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:24:18Z","timestamp":1679862258000},"score":1,"resource":{"primary":{"URL":"https:\/\/immunityageing.biomedcentral.com\/articles\/10.1186\/s12979-023-00336-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1186\/s12979-023-00336-w","relation":{},"ISSN":["1742-4933"],"issn-type":[{"value":"1742-4933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the ASL2 Abruzzo (n.18\u20132013-176). Informed consent was obtained from each subject (or caregiver) included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}